Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Caribou Biosciences announced positive clinical data for its CRISPR-based CAR-T cell therapies. Vispa-cel demonstrated an 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients with a 17.1-month median progression-free survival. CB-011 showed an 83% complete response rate and 91% MRD negativity in heavily pretreated multiple myeloma patients, with 50% maintaining complete response at 15 months.

06/29/2026, 8:00 AM • GlobeNewswire

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences reported positive clinical data for CB-011, its off-the-shelf BCMA-targeted CAR-T cell therapy for relapsed/refractory multiple myeloma. In 12 BCMA-naïve patients at the recommended dose, CB-011 achieved 83% complete response rate, 91% MRD negativity, and 50% of patients remained in complete response at 15 months with a manageable safety profile. The company also presented a case study of a patient previously treated with an approved CAR-T therapy who achieved complete response with CB-011. Dose expansion data is expected in H2 2026.

06/11/2026, 8:00 AM • GlobeNewswire

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

The global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.

01/22/2026, 4:56 AM • GlobeNewswire

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Caribou Biosciences reported promising first clinical data for CB-011, an off-the-shelf allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma, with 92% overall response rate and a manageable safety profile.

11/03/2025, 7:00 AM • GlobeNewswire

CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight

CRISPR therapies are showing significant potential with over 25 key companies developing 30+ pipeline therapies targeting genetic disorders, with promising clinical trials across various disease areas.

10/02/2025, 1:00 PM • GlobeNewswire

Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider

The global gene editing market is projected to grow from USD 6.09 billion in 2024 to USD 15.46 billion by 2032, driven by CRISPR technology advances, therapeutic applications, and significant research funding, with North America leading market development.

09/02/2025, 6:00 AM • GlobeNewswire

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential claims against Caribou Biosciences regarding allegedly misleading statements about its cell therapy product CB-010's safety, efficacy, and financial prospects during July 2023-2024 period.

07/25/2025, 7:35 PM • GlobeNewswire